undamentalytics Newsletter
Sign in

Lisata Therapeutics, Inc. cash flow statement

In fiscal 2025, Lisata Therapeutics, Inc.'s operations generated −$15.9m of cash; it spent $28,000 on capital projects, leaving free cash flow of −$16.0m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−8−21−14−27−47−39−24−21−20−19−16−12
Depreciation and amortisation511122100000
Stock-based pay—10771110332211
Capital spending1611343100000
Free cash flow−25−22−14−30−51−42−25−21−20−19−16−12
Free cash flow after stock pay—−32−21−37−62−52−27−24−22−21−17−13
Dividends paid00000———————
Shares issued2121165917361200011

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: IBIO vs LSTAAIM vs LSTACLDX vs LSTA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Lisata Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lisata Therapeutics, Inc.